FTC Approves the Pfizer-Wyeth Deal And Keeps Their Human Drug Portfolio Intact
This article was originally published in The Pink Sheet Daily
Executive Summary
The FTC requires Pfizer to divest half of Wyeth's animal health business but finds their human drug products, particularly for Alzheimer's disease and osteoporosis, do not compete with each other.
You may also be interested in...
Pfizer Will Retain Infliximab Biosimilar In US After Hospira Acquisition
While European Union requires Pfizer to divest its infliximab candidate in Europe as condition of acquisition, FTC demands only that it sell off four generics.
Par Gets Pumped: Teva To Divest $200 Million Of Products To Acquire Cephalon
FTC requires Teva to sell its generic versions of Actiq and Amrix to Par; Teva will also supply Par with generic Provigil for one year.
Par Gets Pumped: Teva To Divest $200 Million Of Products To Acquire Cephalon
FTC requires Teva to sell its generic versions of Actiq and Amrix to Par; Teva will also supply Par with generic Provigil for one year.